Expression of ER, PR, HER-2 and Ki67 before and after neoadjuvant chemotherapy (NAC) and the relation between their expression and the curative effects of NAC in breast cancer patients

Depression in cancer patients is common and may affect treatment outcome either directly (by lowering defenses) or indirectly (by lowering compliance). Neoadjuvant chemotherapy for advanced uterine cervix or breast cancer is a strenuous undertaking and may lead to depression and impair patients' willingness to comply with the rest of the treatment (eg, surgery or radiotherapy).We compare Beck Depression Inventory (BDI) scores both before and after neoadjuvant chemotherapy in order to verify if depression influences treatment outcome. We studied 22 advanced uterine cervix and 20 breast cancer patients submitted to three courses of neoadjuvant chemotherapy. We used cisplatin and ifosfamide for cervix, and fluorouracil, adriamycin, and cyclophosphamide for breast cancer. We did not identify significant differences in the number of depressed patients, before and after treatment. Cognitive affective, somatic-performance, and total BDI scores were not significantly different from before to after chemotherapy for both breast and uterine cervix cancer. After treatment, the number of depressive breast cancer patients increased while the number of uterine cervix cancer patients decreased. This trend to depression was found more often in less responsive breast cancer patients than in the more responsive cervix cancer patients. We were not able to link depression to treatment failure or success, but patients who responded to treatment were less depressed at the end of treatment.

Download Full-text

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab

Medicine ◽

10.1097/md.0000000000016937 ◽

2019 ◽

Vol 98 (36) ◽

pp. e16937

Author(s):

Xinle Wang ◽

Lijing Cai ◽

Feng Ye ◽

Mengqi Li ◽

Li Ma ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Locally Advanced ◽

Breast Cancer Patients ◽

Elevated Expression ◽

Her 2 ◽

Positive Breast Cancer

Download Full-text

A retrospective study of inflammatory breast cancer patients from seven hospitals in the United Kingdom.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e11062 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e11062-e11062

Author(s):

Saeed Rafii ◽

Christopher John Poole ◽

Adele Francis ◽

Shalini Chaudhri ◽

Daniel Rea

Keyword(s):

Breast Cancer ◽

United Kingdom ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Inflammatory Breast Cancer ◽

Triple Negative ◽

Breast Cancer Patients ◽

The United Kingdom ◽

Her 2 ◽

Clinical Records

e11062 Background: Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer characterised by rapidly progressive breast erythema, pain and tenderness, oedema and paeu d’orange. It is estimated that between 1-4 % of all newly diagnosed breast cancer patients in the United Kingdom have IBC. Methods: We retrospectively identified 51 patients who were treated for IBC at 7 hospitals in the West midlands area of the United Kingdom between 1997 and 2011. Data including patients’ demographics, clinical, radiological and histopathological characteristics were collected from electronic clinical records. The test for HER-2 over-expression was not carried out routinely before 2002, therefore HER-2 status of such patients were assessed retrospectively on the archived tissues. A cox regression analysis was used for statistical assessment of survival and prognostic factors. Results: Median age at diagnosis was 55 years (range 34-83 yrs). Median overall (OS) and progression free survival (PFS) were 32 months (range 7-97 months) and 27 months (range 2-53 months) respectively. The 3–year survival rate for the entire cohort was 32%. Majority of patients were ER and HER-2 positive (49% and 52% respectively). The rate of complete pathological response (pCR) after neoadjuvant chemotherapy was 14%. All cases who had achieved pCR were HER-2 positive who had received anti HER-2 treatment during the neoadjuvant chemotherapy. The OS for the HER-2 positive patients with pCR was not statistically different from the whole cohort (49 vs 32 months, p=0.09) or from the patients with residual disease (49 vs 26 months, p=0.13). Although the triple negative IBC patients consisted 20% of the cohort, no patients in this group had achieved pCR. The OS and PFS for the triple negative patients were 20 and 14 months respectively. Although the rate of pCR was higher in patients treated with taxane compared to those treated with anthracycline containing chemotherapy (35% vs 7%), there was no significant difference in OS between either of these regimens (29 vs 27 months). Conclusions: HER-2 positive IBC patients had higher rate of achieving pCR after neo-adjuvant anti HER-2 therapy. However higher rate of pCR did not improve the OS.

Download Full-text

Can neoadjuvant chemotherapy change clinic pathological and survival parameters in HER-2 positive breast cancer patients?

10.26226/morressier.5b4709836f4cb30010951a5c ◽

2018 ◽

Author(s):

Fiorita Mundim

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Her 2 ◽

Positive Breast Cancer

Download Full-text

Patient-derived xenografts from breast cancer patients before and after neoadjuvant chemotherapy: A prospective study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.11130 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 11130-11130

Author(s):

Judy Caroline Boughey ◽

Jia Yu ◽

Ping Yin ◽

Bowen Gao ◽

Jason P. Sinnwell ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Prospective Study ◽

Cancer Patients ◽

Breast Cancer Patients ◽

Before And After ◽

A Prospective Study

Download Full-text

Impact of pre-treatment lymphocyte monocyte ratio and neutrophil lymphocyte ratio on pathologic response in breast cancer patients receiving neoadjuvant chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e12623 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e12623-e12623

Author(s):

Osama Mosalem ◽

Saud Alsubait ◽

Shouq Kherallah ◽

Venumadhavi Gogineni ◽

Ling Wang ◽

...

Keyword(s):

Breast Cancer ◽

Multivariate Analysis ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Univariate Analysis ◽

Patient Characteristics ◽

Breast Cancer Patients ◽

Her 2 ◽

The Mean ◽

Pre Treatment

e12623 Background: Hematologic markers have been looked at as potential prognostic biomarkers in a variety of cancers. Ni and colleagues (2014) have shown that an elevated pre-treatment lymphocyte-to-monocyte ratio (LMR) was significantly associated with improved disease-free survival (DFS) in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy (NACT). Given the prognostic implications of hematologic inflammatory parameters, we sought to understand if such biomarkers will predict response to neoadjuvant chemotherapy (NACT) in patients with breast cancer. Methods: We conducted a retrospective review of breast cancer patients treated with NACT at our institution (2008-2018). Data on patient characteristics, stage, pathologic characteristics, and blood counts were collected. Blood parameters prior to NACT were used to calculate LMR and neutrophil-to-lymphocyte ratio (NLR). To test the impact of LMR and NLR on pathologic response, a two sample mean test was used first as univariate analysis. Next, logistic regression was employed for multivariate analysis controlling for patient characteristics with interaction of LMR and NLR with ER, PR and HER2 status. Results: A total of 50 patients were included. 38% of patients achieved a pathologic complete response (pCR). The mean LMR was 3.69 (1.4-12.5), and the mean NLR was 2.55 (0.66 – 9.31). On univariate analysis, a high NLR was associated with a higher likelihood of achieving a pCR (OR = 1.64, 95% CI = 1.01-2.63). A high LMR was associated with a higher likelihood of pCR; however, this was not statistically significant (OR = 1.08, 95% CI = 0.78-1.47). On multivariate analysis, patients with HER-2 positive disease with a high LMR had a significantly higher chance of having a pCR (OR = 1.72, 95% CI = 1.06-2.78). Conclusions: Our study showed that NLR was a predictor of pCR in breast cancer patients receiving neoadjuvant chemotherapy. A high NLR was associated with achieving a pCR on univariate analysis. Multivariate analysis suggested that HER-2 positive disease with a high LMR had a significantly higher chance of achieving a pCR. The results of this cohort correlate with previous reports by others showing that pre-NACT LMR and NLR provide prognostic information in patients with breast cancer. Although limited by sample size, this adds to the growing body of literature supporting peripheral blood counts as a biomarker for outcomes in breast cancer.

Download Full-text